Effect of LMWH on Pregnancy Outcome in Women With Multiple Failures of IVF-ET
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
Low-Molecular-Weight-Heparin (LMWH) has been used empirically in patients undergoing in-vitro
fertilization embryo transfer (IVF-ET) with the purpose to aid in improving pregnancy
outcomes. The potential mechanism is that LMWH could exert its anticoagulant effect by
inhibiting factor Xa, reducing the risk of insufficiency blood supply in the very early stage
of pregnancy. Moreover, LMWH is supposed to play a role in manipulating blastocyst
supposition, adhesion, and implantation, as well as trophoblast differentiation and invasion.
However, limited high-quality clinical trials focus on the effectivity of LMWH in IVF-ET, and
the published evidence is not consensus, leading to considerable controversy in the clinical
application of LMWH in IVF-ET patients. Here, investigators try to evaluate the effect of
LMWH on pregnancy outcome in women with multiple failures of IVF-ET via a multi-center
randomized controlled trial.
Phase:
Phase 4
Details
Lead Sponsor:
Shenzhen Zhongshan Urology Hospital
Collaborators:
Renmin Hospital of Wuhan University The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School